博迅生物
(920504)
| 流通市值：3.53亿 | | | 总市值：8.94亿 |
| 流通股本：1709.19万 | | | 总股本：4333.31万 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 26,599,005.35 | 119,810,751.55 | 84,576,132.64 | 52,515,393.67 |
| 营业收入 | 26,599,005.35 | 119,810,751.55 | 84,576,132.64 | 52,515,393.67 |
| 二、营业总成本 | 24,273,581.88 | 107,019,235.22 | 75,863,313.61 | 47,789,310.23 |
| 营业成本 | 16,097,142.76 | 70,355,781.71 | 49,787,907.73 | 31,196,826.83 |
| 税金及附加 | 128,593.39 | 1,044,948.06 | 625,309.39 | 381,688.93 |
| 销售费用 | 2,288,189.25 | 10,037,521.13 | 7,810,883.29 | 4,846,144.68 |
| 管理费用 | 4,464,624.57 | 18,999,484.78 | 13,573,921.53 | 8,666,753.85 |
| 研发费用 | 1,239,647.87 | 6,633,267.31 | 4,107,770.22 | 2,704,449.44 |
| 财务费用 | 55,384.04 | -51,767.77 | -42,478.55 | -6,553.5 |
| 其中:利息费用 | 132,563.84 | 642,856.4 | 492,994.57 | 339,729.62 |
| 其中:利息收入 | 110,115.43 | 734,146.75 | 560,110.78 | 368,653.1 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 85,249.53 | 219,671.24 | 154,375.98 | 128,541.11 |
| 加:投资收益 | 190,844.28 | 1,430,454.32 | 1,072,669.19 | 596,677.54 |
| 资产处置收益 | - | 69,294.85 | 9,124.34 | 9,124.34 |
| 资产减值损失(新) | -288,697.6 | -2,165,944.77 | -1,728,199.67 | -1,602,597.21 |
| 信用减值损失(新) | -838,744.58 | -21,911.09 | -1,065,234.82 | -1,037,722.44 |
| 其他收益 | 268,564.81 | 4,424,267.98 | 2,910,811.68 | 1,372,572.26 |
| 四、营业利润 | 1,742,639.91 | 16,747,348.86 | 10,066,365.73 | 4,192,679.04 |
| 加:营业外收入 | 343.11 | 65,331.98 | 77,539.56 | 77,539.56 |
| 减:营业外支出 | 106.95 | 476,435.26 | 475,433.9 | 332,486.4 |
| 五、利润总额 | 1,742,876.07 | 16,336,245.58 | 9,668,471.39 | 3,937,732.2 |
| 减:所得税费用 | 247,254.06 | 1,421,541.44 | 1,124,707.44 | 301,346.38 |
| 六、净利润 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 | 3,636,385.82 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 | 3,636,385.82 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 | 3,636,385.82 |
| 扣除非经常损益后的净利润 | 1,264,434.43 | 12,664,509.33 | 6,978,648.29 | 2,947,724.47 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.03 | 0.34 | 0.2 | 0.08 |
| (二)稀释每股收益 | 0.03 | 0.34 | 0.2 | 0.08 |
| 九、综合收益总额 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 | 3,636,385.82 |
| 归属于母公司股东的综合收益总额 | 1,495,622.01 | 14,914,704.14 | 8,543,763.95 | 3,636,385.82 |
| 公告日期 | 2026-04-28 | 2026-03-30 | 2025-10-30 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |